对转基托酶抑制剂的结合,亲和和代谢调节活性的评估
Dan Jia1, Chunliang Liu2, Wenyu Liu3
1School of Pharmacy, Second Military Medical University/Naval Medical University, Shanghai, P.R. China; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University/Naval Medical University, Shanghai, P.R. China; National Center for Liver Cancer, Second Military Medical University/Naval Medical University, Shanghai, P.R. China.
Methods in enzymology
|November 7, 2025
概括
转基因酶抑制剂通过调节代谢途径显示出癌症治疗的潜力. 这项研究系统地评估了转基托拉酶抑制剂的结合亲和力和代谢调节活性,证实了其抗瘤潜力.
科学领域:
- 生物化学 生物化学
- 酶学 是一种酶学.
- 代谢途径 代谢途径
背景情况:
- 转基酶 (TKT) 是酸通路中的一个关键酶,对核酸合成和瘤产生至关重要.
- TKT 抑制剂通过调节酶活性和代谢流量,为癌症和传染病提供治疗潜力.
研究的目的:
- 系统地评估转基因酶抑制剂的结合亲和力和代谢调节活性.
- 使用患者衍生器官来评估TKT抑制剂的抗瘤活性.
主要方法:
- 通过2D TKT蛋白生物染色学,DARTS,CETSA,SPR,竞争性结合和分子对接来评估结合亲和力.
- 使用光谱测定和有针对性的代谢物分析确定代谢调节活性.
- 在患者衍生器官中评估的抗瘤活性.
主要成果:
- 转基托酶抑制剂的结合和代谢作用的全面描述.
- 该抑制剂在患者衍生器官中已证明具有抗瘤活性.
- 确定了抑制剂在调节代谢流量的潜力.
结论:
- 评估的转基托拉酶抑制剂对治疗应用具有显著的潜力,特别是在瘤学中.
- 这种系统的评估为进一步开发向转基因酶的药物提供了基础.
- 该抑制剂有效调节代谢途径,并显示出抗瘤功效.
相关概念视频
Enzyme Inhibition
91.4K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.4K
Allosteric Proteins-ATCase
6.4K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.4K
Regulation of Metabolism
11.4K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
11.4K
Protein-Drug Binding: Mechanism and Kinetics
1.6K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.6K
Ligand Binding and Linkage
5.4K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.4K


